Recursion registers 3.5M shares for resale by Tempus Labs as license fee payment

RECURSION PHARMACEUTICALS, INC.

Recursion filed prospectus supplement to register 3,498,393 shares for resale by Tempus Labs.
Shares were issued to Tempus as payment for 2024 annual license fee under Master Agreement dated Nov 2023.
Offering made under exemption from registration; no new issuance or capital raise for Recursion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.